The University of Southampton
University of Southampton Institutional Repository

Early initiation of gonadotropin-releasing hormone antagonist treatment results in a more stable endocrine milieu during the mid- and late-follicular phases: a randomized controlled trial comparing gonadotropin-releasing hormone antagonist initiation on cycle day 2 or 6

Early initiation of gonadotropin-releasing hormone antagonist treatment results in a more stable endocrine milieu during the mid- and late-follicular phases: a randomized controlled trial comparing gonadotropin-releasing hormone antagonist initiation on cycle day 2 or 6
Early initiation of gonadotropin-releasing hormone antagonist treatment results in a more stable endocrine milieu during the mid- and late-follicular phases: a randomized controlled trial comparing gonadotropin-releasing hormone antagonist initiation on cycle day 2 or 6
Objective: to compare the effect of initiating GnRH antagonist (GnRH-a) on cycle day (CD) 2 vs. CD 6 on LH, E2, and P levels in the mid and late follicular phases.

Design: nested study within a multicenter randomized controlled trial.

Setting: reproductive medicine center in an university hospital.

Patient(s): one hundred sixty patients undergoing IVF/intracytoplasmic sperm injection (ICSI).

Intervention(s): recombinant FSH (150–225 IU) was administered daily from CD 2 onward. The study group (CD 2) started GnRH-a cotreatment on CD 2, whereas the control group (CD 6) started on CD 6.

Main Outcome Measure(s): the follicular phase endocrine profile.

Result(s): the LH levels on CD 6 were lower in the CD 2 group (0.6 ± 0.4 vs. 1.9 ± 1.4 IU/L). The CD 2 group demonstrated both lower E2 levels on CD 6 (520.1 ± 429.6 pmol/L vs. 1,071.7 ± 654.2 pmol/L) and on the day of hCG administration (3,341.4 ± 1,535.3 pmol/L vs. 4,573.2 ± 2,445.4 pmol/L). The P levels did not differ on CD 6 or on the day of hCG administration.

Conclusion(s): early initiation of GnRH-a cotreatment results in a more stable endocrine profile, with more physiological levels of E2 and LH during the follicular phase. The effect on clinical outcomes must be established in larger trials
0015-0282
867-874
Hamdine, O.
5bb6c208-02f5-4210-a688-878ee41bafac
Broekmans, F.J.
17ce14de-42f9-43cb-98be-194dc9430888
Eijkemans, M.J.
7a7d87b5-76e0-48b3-85f1-bc0f56942134
Lambalk, C.B.
0fb2b53f-3af5-466d-ad69-8cd0fa43556f
Fauser, B.C.
a74bd2e3-1d5e-43c1-a6e8-c67c4973f484
Laven, J.S.
8777e0d1-9490-4344-bcee-7dfe01eaacd7
Macklon, N.S.
7db1f4fc-a9f6-431f-a1f2-297bb8c9fb7e
Hamdine, O.
5bb6c208-02f5-4210-a688-878ee41bafac
Broekmans, F.J.
17ce14de-42f9-43cb-98be-194dc9430888
Eijkemans, M.J.
7a7d87b5-76e0-48b3-85f1-bc0f56942134
Lambalk, C.B.
0fb2b53f-3af5-466d-ad69-8cd0fa43556f
Fauser, B.C.
a74bd2e3-1d5e-43c1-a6e8-c67c4973f484
Laven, J.S.
8777e0d1-9490-4344-bcee-7dfe01eaacd7
Macklon, N.S.
7db1f4fc-a9f6-431f-a1f2-297bb8c9fb7e

Hamdine, O., Broekmans, F.J., Eijkemans, M.J., Lambalk, C.B., Fauser, B.C., Laven, J.S. and Macklon, N.S. (2013) Early initiation of gonadotropin-releasing hormone antagonist treatment results in a more stable endocrine milieu during the mid- and late-follicular phases: a randomized controlled trial comparing gonadotropin-releasing hormone antagonist initiation on cycle day 2 or 6. Fertility and Sterility, 100 (3), 867-874. (doi:10.1016/j.fertnstert.2013.05.031). (PMID:23809501)

Record type: Article

Abstract

Objective: to compare the effect of initiating GnRH antagonist (GnRH-a) on cycle day (CD) 2 vs. CD 6 on LH, E2, and P levels in the mid and late follicular phases.

Design: nested study within a multicenter randomized controlled trial.

Setting: reproductive medicine center in an university hospital.

Patient(s): one hundred sixty patients undergoing IVF/intracytoplasmic sperm injection (ICSI).

Intervention(s): recombinant FSH (150–225 IU) was administered daily from CD 2 onward. The study group (CD 2) started GnRH-a cotreatment on CD 2, whereas the control group (CD 6) started on CD 6.

Main Outcome Measure(s): the follicular phase endocrine profile.

Result(s): the LH levels on CD 6 were lower in the CD 2 group (0.6 ± 0.4 vs. 1.9 ± 1.4 IU/L). The CD 2 group demonstrated both lower E2 levels on CD 6 (520.1 ± 429.6 pmol/L vs. 1,071.7 ± 654.2 pmol/L) and on the day of hCG administration (3,341.4 ± 1,535.3 pmol/L vs. 4,573.2 ± 2,445.4 pmol/L). The P levels did not differ on CD 6 or on the day of hCG administration.

Conclusion(s): early initiation of GnRH-a cotreatment results in a more stable endocrine profile, with more physiological levels of E2 and LH during the follicular phase. The effect on clinical outcomes must be established in larger trials

This record has no associated files available for download.

More information

Published date: September 2013
Organisations: Human Development & Health

Identifiers

Local EPrints ID: 359609
URI: http://eprints.soton.ac.uk/id/eprint/359609
ISSN: 0015-0282
PURE UUID: bd5f5d62-b3a9-43a2-9b88-76c9ab921dd1

Catalogue record

Date deposited: 07 Nov 2013 11:59
Last modified: 08 Jan 2022 09:12

Export record

Altmetrics

Contributors

Author: O. Hamdine
Author: F.J. Broekmans
Author: M.J. Eijkemans
Author: C.B. Lambalk
Author: B.C. Fauser
Author: J.S. Laven
Author: N.S. Macklon

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×